Neos Therapeutics to Present at BMO 2020 Prescriptions for Success Healthcare Conference
Neos Therapeutics (Nasdaq: NEOS) announced that CEO Jerry McLaughlin will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neos Therapeutics (Nasdaq: NEOS) announced that CEO Jerry McLaughlin will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 4:30 p.m. ET. The presentation will provide an overview of the company's central nervous system-focused pharmaceutical products, including Adzenys XR-ODT and Cotempla XR-ODT for ADHD treatment. A live webcast will be available on their Investor Relations page, with a replay accessible for 30 days following the event.
Details
News Market Reaction – NEOS
The recorded move for NEOS in the trading session of this news was +0.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS and FORT WORTH, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020, at 4:30 p.m. ET.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Following the presentation, a replay of the webcast will be available on Neos’ website for 30 days.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products. The Company markets Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD. The Company also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions. Additional information about Neos is available at www.neostx.com.
CONTACTS:
Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah.mccabe@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.